Background Despite the availability of effective vaccines against COVID-19, booster
vaccinations are needed to maintain vaccine-induced protection against variant strains and …

Abstract Background The Ad26. COV2. S vaccine is a recombinant, replication-incompetent
human adenovirus type 26 vector encoding full-length severe acute respiratory syndrome …

Abstract Background The Ad26. COV2. S vaccine was highly effective against severe–
critical coronavirus disease 2019 (Covid-19), hospitalization, and death in the primary phase …

Background Efficacious vaccines are urgently needed to contain the ongoing coronavirus
disease 2019 (Covid-19) pandemic of infection with severe acute respiratory syndrome …

Importance Vaccination against the SARS-CoV-2 virus is critical to control the pandemic.
Randomized trials demonstrated efficacy of the single-dose Ad26. COV2. S COVID vaccine …

Background We report the clinical efficacy against COVID-19 infection of BBV152, a whole
virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist …

ABSTRACT BACKGROUND The ongoing coronavirus disease (COVID)-19 pandemic
caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be …

Background The literature on first generation COVID-19 vaccines show they were less
effective against new SARS-CoV-2 variants of concern including Omicron (BA. 1, BA. 2, BA …

Background To mitigate the effects of COVID-19, a vaccine is urgently needed. BBV152 is a
whole-virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist …

Background COVID-19 vaccines with alternative strain compositions are needed to provide
broad protection against newly emergent SARS-CoV-2 variants of concern. This study …